SCHEMBL17875744

SCHEMBL17875744

c1ccc(-c2cc(-c3ccccc3)cc(-c3ccc4c(c3)-c3ccc(-c5ccc6oc7ccccc7c6c5)cc3CSC4)c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 4/20 0.40
PLA2G4A P47712 4/20 0.40
PLA2G10 O15496 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
PRKDC P78527 3/20 0.34
TDP2 O95551 1/20 0.34
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
AHR P35869 1/20 0.33
TYRO3 Q06418 1/20 0.32
NTRK2 Q16620 1/20 0.32
CLK4 Q9HAZ1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17875766 1.00 PLA2G2A (0.40) PLA2G2APLA2G4APLA2G10SMN1; SMN2KDM4E
SCHEMBL17875795 0.95 PLA2G2A (0.43) PLA2G2APLA2G4APLA2G10SMN1; SMN2KDM4E
SCHEMBL17875733 0.94 MAPT (0.40) PLA2G2APLA2G4APLA2G10SMN1; SMN2KDM4E
SCHEMBL17875736 0.93 MMP12 (0.38) PLA2G2APLA2G4APLA2G10SMN1; SMN2KDM4E
SCHEMBL17875794 0.93 MMP12 (0.38) PLA2G2APLA2G4APLA2G10SMN1; SMN2KDM4E
SCHEMBL17875740 0.90 MEN1 (0.37) PLA2G2APLA2G4APLA2G10SMN1; SMN2KDM4E
SCHEMBL17875763 0.90 KMT2A (0.35) PLA2G2APLA2G4APLA2G10SMN1; SMN2KDM4E
SCHEMBL17875748 0.90 KMT2A (0.35) PLA2G2APLA2G4APLA2G10SMN1; SMN2KDM4E
SCHEMBL17875792 0.89 MAPT (0.44) PLA2G2APLA2G4APLA2G10SMN1; SMN2KDM4E
SCHEMBL17875764 0.88 CYP11B1 (0.40) TDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10581000-B2 Condensed cyclic compound and organic light-emitting device including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-03-03 US disclosed
US-20160190482-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2016-06-30 US disclosed
US-20160190482-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10581000-B2 Condensed cyclic compound and organic light-emitting device including the same CRY1, CRY2, CCNE2 PLA2G2A 4359/4885PLA2G4A 4087/4885PLA2G10 4067/4885
US-20160190482-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CRY2, CCNE2 PLA2G2A 4359/4885PLA2G4A 4087/4885PLA2G10 4067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.